Urgent Legal Action for CS Disco, Five Below, and Humana Shareholders
UPDATE: Urgent legal developments for shareholders of CS Disco Inc. (NYSE: LAW), Five Below, Inc. (NASDAQ: FIVE), and Humana Inc. (NYSE: HUM) have emerged as class action complaints survive motions to dismiss. These allegations raise serious concerns about securities fraud that could impact shareholder investments significantly.
On October 24, 2025, the Grabar Law Office confirmed that class action complaints against CS Disco Inc. have survived a crucial legal hurdle. Current shareholders who have held shares since before September 2, 2021, can now seek corporate reforms and a potential return of funds with no cost to them. This legal action arose from claims that the former CEO misled investors regarding customer spending trends, which were allegedly spiky rather than the steady growth portrayed.
In parallel, Five Below, Inc. shareholders face similar issues. The court ruled that key allegations against the company, including misleading information about its financial strength, survived a motion to dismiss. Shareholders holding Five Below shares since before December 1, 2022, are encouraged to act. The complaint alleges that management failed to disclose serious operational challenges, impacting the outlook for 2024.
What You Should Do Now: If you hold shares in either company, it’s critical to act swiftly. For CS Disco, visit https://grabarlaw.com/the-latest/csdisco-shareholder-investigation/ or contact Joshua Grabar at [email protected]. For Five Below, information is available at https://grabarlaw.com/the-latest/five-shareholder-investigation/.
Meanwhile, Humana Inc. is also in the legal spotlight as investigations continue into potential breaches of fiduciary duties by its officers. Shareholders who purchased shares before July 27, 2022, may seek reforms and financial restitution. Allegations suggest that the company downplayed significant medical cost pressures linked to increased healthcare utilization rates.
Immediate Action Needed: If you hold shares in Humana, visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/ for vital details.
Additionally, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is under scrutiny for alleged discrepancies in statements regarding its FDA compliance. Shareholders who purchased shares prior to March 29, 2024, are also urged to evaluate their legal options.
As these developments unfold, shareholders are reminded of the urgent need to seek legal advice and explore their options for potential recovery.
For all inquiries regarding these cases, contact Joshua Grabar at 267-507-6085 or via email at [email protected]. The time to act is NOW—don’t miss your chance to protect your investments!
